Shanghai Kaibao Pharmaceutical CO.,Ltd (SHE:300039)

Market Cap	6.15B
Revenue (ttm)	1.47B
Net Income (ttm)	375.58M
Shares Out	1.05B
EPS (ttm)	0.36
PE Ratio	17.63
Forward PE	n/a
Dividend	0.10 (1.70%)
Ex-Dividend Date	Jun 19, 2024

Volume	14,104,900
Average Volume	29,574,995
Open	6.07
Previous Close	5.90
Day's Range	5.88 - 6.07
52-Week Range	4.90 - 7.60
Beta	0.26
RSI	39.32
Earnings Date	Apr 16, 2025

About SHE:300039

Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern Chinese medicines primarily in China. Its primary products include Tanreqing injection for the treatment of pneumonia, acute and chronic bronchitis, and upper respiratory tract infection; Tanreqing capsules that clears heat and detoxifies and removes phlegm; tiopronin for injection, which improves liver function of various acute and chronic hepatitis; Tiopronin enteric-coated tablets for adjuvant treatment of chronic hepatitis; and Xiongd...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,325
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300039

Financial Performance

In 2024, SHE:300039's revenue was 1.47 billion, a decrease of -7.57% compared to the previous year's 1.59 billion. Earnings were 375.58 million, an increase of 14.55%.